nach oben

Erschienen in:

01.06.2014 | Original Article

Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson’s disease

verfasst von: Nadella Kumudini, Addepally Uma, Shaik Mohammad Naushad, Rukmini Mridula, Rupam Borgohain, Vijay Kumar Kutala

Erschienen in: Neurological Sciences | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

The vulnerability of dopaminergic neurons to environmental exposures in sporadic Parkinson’s disease (PD) has been attributed to altered detoxification by xenobiotic metabolizing genes. Hence, we investigated the influence of genetic polymorphisms in xenobiotic metabolic pathway (CYP1A1 m1, CYP1A1 m2, CYP1A1 m4, COMT p.H108L, GSTT1, and GSTM1) on the susceptibility to PD. We used PCR–RFLP for CYP1A1 and COMT genotyping; multiplex-PCR for GSTT1 and GSTM1 deletion analysis; and spectrophotometric methods to evaluate the oxidative stress markers. Results showed association of CYP1A1 m1 (OR: 2.38, 95 % CI: 1.76–3.22) and COMT p.H108L (OR: 2.08 95 % CI: 1.56–2.77) polymorphisms with risk for PD. Male patients carrying combination of COMT p.H108L and CYP1A1 m1 variant alleles showed an early onset of the disease. There was a significant increase in oxidative stress makers such as malondialdehyde and protein carbonyls; and decrease in glutathione levels in PD cases compared to controls (P < 0.05). To conclude, CYP1A1 m1, COMT p.H108L polymorphisms were associated with PD risk, and sexual dimorphism was observed in these associations.

de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535PubMedCrossRef

Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM (2003) Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157(11):1015–1022CrossRef

Warner TT, Schapira AH (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53(Suppl 3):16–23CrossRef

Kurtz JF (1992) An overview of epidemiology of Parkinsonism. In: Hefti F, Weiner WJ (eds) Progress in Parkinson’s disease research. Mount Kisw Futura Publishing, New York, pp 119–169

Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson’s disease. Neurotox Res 5:165–176PubMedCrossRef

Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47(6 Suppl 3):161–170CrossRef

Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269PubMedCrossRef

Jakoby WB, Ziegler DM (1990) The enzymes of detoxication. J Biol Chem 265(34):20715–20718PubMed

Smith CA, Smith G, Wolf CR (1994) Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 30A(13):1921–1935PubMedCrossRef

10.

Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B (1997) Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 324:25–28PubMedCentralPubMed

11.

Takakubo F, Yamamoto M, Ogawa N, Yamashita Y, Mizuno Y, Kondo I (1996) Genetic association between cytochrome P450IA1 gene and susceptibility to Parkinson’s disease. J Neural Transm 103:843–849PubMedCrossRef

12.

Stroombergen MC, Waring RH (1999) Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum Exp Toxicol 18:141–145PubMedCrossRef

13.

Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Mozzoni P, Haites N, Wettinger SB, Mutti A, Otelea M, Seaton A, Soderkvist P, Felice A, Geoparkinson Study Group (2007) Gene-environment interactions in parkinsonism and Parkinson’s disease: the geoparkinson study. Occup Environ Med 64:673–680PubMedCentralPubMedCrossRef

14.

Kunugi H, Nanko S, Ueki A, Otsuka E, Hattori M, Hoda F, Vallada HP, Arranz MJ, Collier DA (1997) High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson’s disease. Neurosci Lett 221(2–3):202–204PubMedCrossRef

15.

Punia S, Das M, Behari M, Dihana M, Govindappa ST, Muthane UB, Thelma BK, Juyal RC (2011) Leads from xenobiotic metabolism genes for Parkinson’s disease among north Indians. Pharmacogenet Genomics 21(12):790–797PubMedCrossRef

16.

Placer ZA, Crushman LL, Johnson BC (1966) Estimation of products of lipid peroxidation (malonylaldehyde) in biochemical systems. Anal Biochem 16(2):359–364PubMedCrossRef

17.

Rajesh M, Sulochana KN, Coral K, Punitham R, Biswas J, Babu K, Ramakrishnan S (2004) Determination of carbonyl group content in plasma proteins as a useful marker to assess impairment in antioxidant defense in patients with Eales’ disease. Indian J Ophthalmol 52(2):139–144PubMed

18.

Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82(1):70–77PubMedCrossRef

19.

Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW (2006) Elevated levels of oxidized cholesterol metabolites in lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2:249–253PubMedCrossRef

20.

Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K (2007) Oxidative damage in nucleic acids and Parkinson’s disease. J Neurosci Res 85:919–934PubMedCrossRef

21.

Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson’s disease: is this the elephant in the room? Biomed Pharmacother 62:236–249PubMedCrossRef

22.

Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53:26–36CrossRef

23.

Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33(3):305–310PubMedCrossRef

24.

Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM et al (1996) Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 20(7):1159–1170PubMedCrossRef

25.

Venkateshappa C, Harish G, Mythri RB, Mahadevran A, Barath MMS, Shankar SK (2012) Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implication for Parkinson’ disease. Neurochem Res 37(2):358–369PubMedCrossRef

26.

Wang J, Liu Z, Chen B (2000) Association between cytochrome P-450 enzyme gene polymorphisms and Parkinson’s disease. Zhonghua Yi Xue Za Zhi 80(8):585–587PubMed

27.

Chan DK, Mellick GD, Buchanan DD, Hung WT, Ng PW, Woo J, Kay R (2002) Lack of association between CYP1A1 polymorphism and Parkinson’s disease in a Chinese population. J Neural Transm 109(1):35–39PubMedCrossRef

28.

Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, Fukushima W, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Fukuoka Kinki Parkinson’s Disease Study Group (2011) Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson’s disease in a Japanese population. BMC Neurol 11:89PubMedCentralPubMedCrossRef

29.

Lechun L, Yu S, Pengling H, Changqi H (2013) The COMT Val158Met polymorphism as an associated risk factor for Parkinson’s disease in Asian rather than Caucasian populations. Neurol India 61(1):12–16PubMedCrossRef

30.

de Lau LM, Verbaan D, Marinus J, Heutink P, van Hilten JJ (2012) Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease. Mov Disord 27(1):132–135PubMedCrossRef

31.

Klebe S, Golmard JL, Nalls MA, Saad M, Singleton AB, Bras JM, Hardy J, Simon-Sanchez J, Heutink P, Kuhlenbäumer G, Charfi R, Klein C, Hagenah J, Gasser T, Wurster I, Lesage S, Lorenz D, Deuschl G, Durif F, Pollak P, Damier P, Tison F, Durr A, Amouyel P, Lambert JC, Tzourio C, Maubaret C, Charbonnier-Beaupel F, Tahiri K, Vidailhet M, Martinez M, Brice A, Corvol JC, French Parkinson’s Disease Genetics Study Group, International Parkinson’s Disease Genomics Consortium (IPDGC) (2013) The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson’s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry 84(6):666–673PubMedCentralPubMedCrossRef

32.

Wahner AD, Glatt ChE, Bronstein JM, Ritz B (2007) Glutathione S-transferase mu, omega, pi and theta class variants and smoking in Parkinson’s disease. Neurosci Lett 413(3):274–278PubMedCentralPubMedCrossRef

33.

Kelada SN, Stapleton PL, Farin FM, Bammler TK, Eaton DL, Smith-Weller T, Franklin GM, Swanson PD, Longstreth WT Jr, Checkoway H (2003) Glutathione S-transferases M1, T1 and P1 polymorphisms and Parkinson’s disease. Neurosci Lett 337(1):5–8PubMedCrossRef

34.

Perez-Pastene C, Graumann R, Diaz-Grez F, Miranda M, Venegas P, Godoy OT, Layson L, Villagra R, Matala JM, Herrera L, Segura-Aguilar J (2007) Association of GST M1 oxidative changes and possible effects of polymorphism of antioxidant enzymes in neurodegenerative disease null polymorphism with Parkinson’s disease in a Chilean population with strong Amerindian genetic component. Neurosci Lett 418(2):181–185PubMedCrossRef

35.

Stroombergen MC, Waring RH (1999) Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum Exp Toxicol 18(3):141–145PubMedCrossRef

36.

Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG (1998) Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet 352:1344–1346PubMedCrossRef

37.

Mellick GD (2006) CYP450, genetics and Parkinson’s disease: gene x environment interactions hold the key. J Neural Transm Suppl 70:159–165PubMedCrossRef

Titel: Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson’s disease
verfasst von: Nadella Kumudini
Addepally Uma
Shaik Mohammad Naushad
Rukmini Mridula
Rupam Borgohain
Vijay Kumar Kutala
Publikationsdatum: 01.06.2014
Verlag: Springer Milan
Erschienen in: Neurological Sciences / Ausgabe 6/2014
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-013-1622-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2014

Cinepazide maleate protects PC12 cells against oxygen–glucose deprivation-induced injury

Activation of NMDA receptor of glutamate influences MMP-2 activity and proliferation of glioma cells

An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation

Two cases of cerebral venous sinus thrombosis due to intracranial hypotension after epidural anesthesia as a diagnostic challenge

Spinal myoclonus after cervical spine extension procedure: case report